Pfizer Inc. PFE,
and German partner BioNtech SE BNTX,
an in vitro study on Friday found that their COVID-19 vaccine neutralizes the two new infectious variants that have emerged in the UK and South Africa. The results were published on the bioRxiv introductory service and have not yet been peer-reviewed. “Although these two rapidly spreading viruses are different, they share the N501Y mutation, which is located at the receptor binding site of the spike protein and leads to the spike protein binding of the virus. tighter to its receptor., ”the companies said in a joint statement.“ It has been shown to affect mice more effectively. “The lawsuit found that the serra of 20 participants in Phase 3 trials neutralized the virus with the simulation as well as neutralized the virus without the simulation,” the statement said. Pfizer, BioNTech, and UTMB are encouraged by these early, in vitro study findings, “the statement said, although more research is needed. The vaccine has been licensed for emergency use in the U.S. and is being used in BioNTech shares have already jumped 6% on the news, while Pfizer was up 0.6% BioNTech shares have gained 116% in the last 12 months, and the SPDR S&P Biotech ETF XBI,
achieved 58% and the S&P 500 SPX,
has acquired 17.5%.